Yttrium-90-labeled ibritumomab tiuxetan for primary CNS lymphoma

11512 Background: Salvage treatment has not yet been established in primary CNS lymphoma (PCNSL). Here we report first results of an ongoing phase II study with a single treatment course of Y-90 an...